← Human Trials & Peer-Reviewed Studies
Electronic cigarette nicotine delivery can exceed that of combustible cigarettes: a preliminary report.
Plain-language guide to PMID 26324250 (2016): double-blind randomized controlled trial of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 26324250
- Journal
- Tobacco control
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Ramôa CP et al. (9 authors)
- DOI
- 10.1136/tobaccocontrol-2015-052447
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.
Venous blood was sampled to determine plasma nicotine concentration.
Why It Was Studied
Electronic cigarettes (ECIGs) aerosolise a liquid that usually contains propylene glycol and/or vegetable glycerine, flavourants and the dependence-producing drug, nicotine, in various concentrations.
This laboratory study examined the relationship between liquid nicotine concentration and plasma nicotine concentration and puffing behaviour in experienced ECIG users.
Who Took Part
By PubMed's age tags, the people studied were young adults and adults, both men and women.
In each session, participants completed two 10-puff ECIG-use bouts (30 s puff interval) separated by 60 min.
How the Study Was Run
In design terms this was a randomized and double-blind study.
Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).
Puff duration, volume and average flow rate were measured.
What Was Measured
The subject headings attached to it are Administration, Inhalation, Aerosols, Electronic Nicotine Delivery Systems, Nicotine, Nicotinic Agonists, Smoking and Smoking Cessation.
The authors tagged it with the keywords Addiction and Electronic nicotine delivery devices.
What This Means in Plain Language
The paper is a randomized and double-blind study of Therapeutic nicotine (patch, non-peptide).
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2016 (Tobacco control), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.